H2020-JTI-IMI2-2020-23-two-stage
H2020-JTI-IMI2-2020-22-single-stage
24 junio, 2020
Suso Lasso, médico del Servet que enfermó de covid: «El miedo que no tuve en el hospital lo tengo ahora»
24 junio, 2020Topics:
- Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
- Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance. This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
- Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Topic 5 Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Topic 6: Behavioural model of factors affecting patient adherence
Tipos de acción: Research and Innovation Action (RIA)
Presupuesto: IMI2 JU = 47.790.000 Euros (+ EFPIA y Socios IMI2 JU = 47.360.000 Euros)
Fecha limite: 29 de septiembre de 2020
Cierre 1ª fase: 29 de septiembre de 2020
Cierre 2ª fase: 17 de marzo de 2021